公开(公告)号：EP4397661A1

公开(公告)日：2024-07-10

申请号：EP22863588.4

申请日：2022-09-01

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： ZHANG, Chen ,  LIAO, Yuting ,  LU, Yonghua ,  ZHAO, Junbin ,  ZOU, Sijia ,  YU, Yan ,  TANG, Pingming ,  GAO, Qiu ,  CHENG, Xinfan ,  YE, Fei ,  LI, Yao ,  NI, Jia ,  YAN, Pangke

IPC分类号： C07D487/04 ,  C07K5/083 ,  A61K31/5377 ,  A61P35/00

CPC分类号： C07D487/04 ,  A61K31/5377 ,  A61P35/00 ,  C07K5/0804

摘要： A compound of general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, an intermediate thereof, and a use thereof in Bcl-2 family proteinsrelated diseases such as cancer. B-L-K (I)

公开(公告)号：EP4461735A1

公开(公告)日：2024-11-13

申请号：EP23737031.7

申请日：2023-01-04

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： ZHANG, Chen ,  LIAO, Yuting ,  ZHAO, Chenfei ,  YU, Yan ,  TANG, Pingming ,  MA, Junjie ,  CHEN, Xiaogang ,  YUAN, Shuai ,  CHENG, Xinfan ,  YE, Fei ,  LI, Yao ,  NI, Jia ,  YAN, Pangke

IPC分类号： C07D519/00 ,  C07D487/04 ,  A61K31/519 ,  A61K47/55 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00

摘要： The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, and an intermediate thereof, and use thereof in IRAK4-related diseases such as an autoimmune disease, an inflammatory disease or cancer. B-L-K (I)

公开(公告)号：EP4389742A1

公开(公告)日：2024-06-26

申请号：EP22857877.9

申请日：2022-08-18

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： ZHANG, Chen ,  LIAO, Yuting ,  ZHU, Guozhi ,  TANG, Dachao ,  YU, Yan ,  TANG, Pingming ,  CHENG, Xinfan ,  LI, Yao ,  NI, Jia ,  YAN, Pangke

IPC分类号： C07D401/06 ,  C07D401/02 ,  C07D401/14 ,  C07D403/06 ,  C07D403/02 ,  C07D403/14 ,  A61K31/454 ,  A61P13/12

CPC分类号： A61K31/454 ,  A61P13/12 ,  C07D401/14 ,  C07D403/02 ,  C07D403/06 ,  C07D403/14 ,  C07D401/02 ,  C07D401/06

摘要： Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating a disease associated with the activity or expression quantity of complement factor B.

公开(公告)号：EP4385985A1

公开(公告)日：2024-06-19

申请号：EP22855498.6

申请日：2022-08-11

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： ZHANG, Chen ,  LIAO, Yuting ,  CHEN, Xiaogang ,  XU, Jinxiong ,  YU, Yan ,  TANG, Pingming ,  GAO, Qiu ,  ZHAO, Junbin ,  LI, Yupeng ,  CHENG, Xinfan ,  ZHU, Guozhi ,  YE, Fei ,  LI, Yao ,  NI, Jia ,  YAN, Pangke

IPC分类号： C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  A61K31/444 ,  A61K31/496 ,  A61K31/517 ,  A61P35/00

CPC分类号： A61K31/444 ,  A61K31/496 ,  A61K31/517 ,  A61P35/00 ,  C07D401/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D471/04

摘要： Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof and an intermediate thereof; and the use thereof in AR-related diseases such as cancer. B-L-K (I)

公开(公告)号：EP4332100A1

公开(公告)日：2024-03-06

申请号：EP22795017.7

申请日：2022-04-29

申请人： Xizang Haisco Pharmaceutical Co., Ltd.

发明人： ZHANG, Chen ,  WANG, Jianmin ,  ZHAO, Chenfei ,  QIAN, Guofei ,  MA, Junjie ,  HUANG, Zhenggang ,  YUAN, Shuai ,  HUANG, Anbang ,  ZHENG, Shaolong ,  LI, Kai ,  YU, Yan ,  YE, Fei ,  TANG, Pingming ,  LI, Yao ,  NI, Jia ,  YAN, Pangke

IPC分类号： C07D401/14 ,  C07F9/53 ,  A61K31/506 ,  A61K31/675 ,  A61P35/00

摘要： Provided are the compound shown in general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, and a use thereof in EGFR-related diseases such as cancer. B-L-K (I)